Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
Date:10/28/2008

ates. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the United States die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the United States are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statemen
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Anadys Pharmaceuticals to Present at Bio Investor Forum
2. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
5. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
6. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
11. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Daily Gossip issued a press release ... will be published on their website at the end ... to inform readers about the information they will find on ... working at Daily Gossip, the article is a review of ... Hiller has understood during the vast research he has performed ...
(Date:6/19/2013)... PrettySkin4Less announces it is stocking up with the ... skin care manufacturer EMINENCE to meet customer demands. These ... active organic ingredients to promote actual change rather than ... offer. For this reason it’s not hard to see ... products that do what they say they will and ...
(Date:6/19/2013)... UT (PRWEB) June 19, 2013 ... , In July 2013, Orriant is launching a ... rates, and maintain compliance with regulations. New ... to receive wellness incentives if their employer offers ... they have been compliant with these standards for ...
(Date:6/19/2013)... York, New York (PRWEB) June 19, 2013 ... pancreatitis and pancreatic cancer continue to mount in courts ... U.S. Food & Drug Administration (FDA) recently held a ... diabetes drugs known as incretin mimetics. According to ... seek additional data from the makers of Januvia and ...
(Date:6/19/2013)... what is believed to be the largest follow-up record ... dystonia a movement disorder that can cause crippling ... good success rates and lasting benefits. , Michele Tagliati, ... Cedars-Sinai Medical Center,s Department of Neurology, and Ron L. ... Beth Israel Deaconess Medical Center in Boston, published the ...
Breaking Medicine News(10 mins):Health News:The Jump Manual Review: Reveals Hiller’s Method of Vertical Jump Training 2Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2
... for health care reform programs will result in the potential ... coverage in California, according to a new policy brief from ... The number represents approximately 20 percent of all uninsured children ... 40,000 may be eligible for coverage but may not apply, ...
... 2011) Autism Speaks, the world,s largest autism science ... for Autism have joined HP,s "Hacking Autism" initiative, which ... people with autism. "Hacking Autism" will crowd source ideas ... families and practitioners, and will engage developers and designers ...
... young adult mice that a lone brain stem cell is capable ... and glia important types of brain cells but also ... cells. A report on their study appears June 24 in ... has the capacity to generate both neurons, which send and receive ...
... , THURSDAY, June 30 (HealthDay News) -- Cotton swabs ... infections, according to researchers. Daily use of dry ... patients who,d undergone appendectomy dramatically reduced surgical site infections, ... underwent the daily routine developed infections, compared with 19 ...
... , THURSDAY, June 30 (HealthDay News) -- The number of ... levels has dropped by more than half over the past ... 6.3 per 100,000 in 2009, a new study reveals. ... decreased, the health effects from lead exposure are well characterized," ...
... the Sahlgrenska Academy, University of Gothenburg, have identified a ... The proteins, which carry specific sugar molecules, are found ... Alzheimer,s disease than in patients with dementia caused by ... treatment in the future. , Gran Larson is a ...
Cached Medicine News:Health News:Up to 220,000 California children excluded from health care reform due to immigrant status 2Health News:Autism Speaks and Flutie Foundation join HP's 'Hacking Autism' to develop touch apps for autism 2Health News:Autism Speaks and Flutie Foundation join HP's 'Hacking Autism' to develop touch apps for autism 3Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:Cotton Swabs Help Prevent Surgical Site Infections: Study 2Health News:On-the-Job Lead Exposures Falling, But Still a Problem: CDC 2Health News:New clues to the cause of Alzheimer's disease 2
(Date:6/19/2013)... /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX, "Chindex" or ... in China through the ... private hospitals and affiliated ambulatory clinics, today announced ... Rehabilitation Hospital ("BJU Rehab Hospital"), one of the ... ("UFH") network. On June 19, 2013, the Company ...
(Date:6/19/2013)... , June 19, 2013 DST Health ... and services to health plans, integrated delivery systems, and ... Medical Drug Management Service (MDMS) has jumped ... edit and automate the pricing of medical prescription drug ... efficiencies by automating their medical drug claims processes. As ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- ... a new specialty pharmaceutical company dedicated to ... innovative injectable and sustained release drug therapies ... medical needs, today announced the acquisition of ... Technology®) platform and associated product pipeline. Acquisition ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
... Calif., Oct. 25 Applied Seals North ... products used in ultraclean manufacturing of nanoelectronics and ... capabilities at its Silicon Valley headquarters with the ... Chen joins the company,s product engineering team to ...
... EAST BRUNSWICK, N.J., Oct. 25 Savient Pharmaceuticals, Inc. (Nasdaq: ... process to identify, following the approval of KRYSTEXXA™ by the ... the sale of the Company did not result in a ... directors will continue to evaluate strategic alternatives available to the ...
Cached Medicine Technology:Applied Seals North America Bolsters Engineering and Applications Services in Silicon Valley With Addition of Design Engineer 2Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 2Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 3
Fulgurating Electrode, 3 F...
... The ACMI USA Series ACN-2 Flexible CystoNephroscope ... It is ideal for office practice. The ... accommodates a full range of operating instruments ... outer diameter, and beveled, UltraGlide covered tip ...
Inquire...
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: